| Asthma
Trelegy Ellipta vs Xolair
Side-by-side clinical, coverage, and cost comparison for asthma.Deep comparison between: Trelegy Ellipta vs Xolair with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXolair has a higher rate of injection site reactions vs Trelegy Ellipta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xolair but not Trelegy Ellipta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Trelegy Ellipta
Xolair
At A Glance
Oral inhalation
Once daily
ICS/LAMA/LABA
SC injection
Every 2-4 weeks
Anti-IgE antibody
Indications
- Chronic Obstructive Airway Disease
- Asthma
- Asthma
- Chronic rhinosinusitis with multiple nasal polyps
- IgE-mediated food allergy
- Chronic Spontaneous Urticaria
Dosing
Chronic Obstructive Airway Disease 1 actuation of TRELEGY ELLIPTA 100/62.5/25 mcg once daily by oral inhalation; rinse mouth with water without swallowing after each dose.
Asthma 1 actuation of TRELEGY ELLIPTA 100/62.5/25 mcg or 200/62.5/25 mcg once daily by oral inhalation; rinse mouth with water without swallowing after each dose.
Asthma 75 to 375 mg SC every 2 or 4 weeks based on serum total IgE level (IU/mL) measured before the start of treatment and body weight (kg).
Chronic rhinosinusitis with multiple nasal polyps 75 to 600 mg SC every 2 or 4 weeks based on serum total IgE level (IU/mL) measured before the start of treatment and body weight (kg).
IgE-mediated food allergy 75 to 600 mg SC every 2 or 4 weeks based on serum total IgE level (IU/mL) measured before the start of treatment and body weight (kg).
Chronic Spontaneous Urticaria 150 or 300 mg SC every 4 weeks; dosing is not dependent on serum IgE level or body weight.
Contraindications
- Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate, umeclidinium, vilanterol, or any excipient
- Severe hypersensitivity reaction to omalizumab or any ingredient of XOLAIR
Adverse Reactions
Most common (>=1%) Headache, back pain, nasopharyngitis, upper respiratory tract infection, bronchitis, dysgeusia, cough, oropharyngeal pain, diarrhea, influenza, sinusitis, oral candidiasis, arthralgia, dysphonia, pneumonia, urinary tract infection, rhinitis, constipation, gastroenteritis
Serious Serious asthma-related events (hospitalizations, intubations, death), oropharyngeal candidiasis, pneumonia in COPD, immunosuppression and risk of infections, hypercorticism and adrenal suppression, paradoxical bronchospasm, cardiovascular effects, reduction in bone mineral density, worsening of narrow-angle glaucoma, worsening of urinary retention
Postmarketing Palpitations, blurred vision, eye pain, glaucoma, intraocular pressure increase, hypersensitivity reactions (anaphylaxis, angioedema, rash, urticaria), hyperglycemia, muscle spasms, tremor, anxiety, dysuria, urinary retention
Most common (>=1%) Arthralgia, pain, injection site reactions, headache, fatigue, dizziness, pruritus, nasopharyngitis, sinusitis, upper respiratory tract infection, dermatitis, earache
Serious Anaphylaxis, malignancies, cardiovascular and cerebrovascular events
Postmarketing Anaphylaxis, eosinophilic conditions, fever with arthralgia and rash (serum sickness-like), severe thrombocytopenia, hair loss
Pharmacology
TRELEGY ELLIPTA combines fluticasone furoate (ICS), umeclidinium (long-acting muscarinic antagonist), and vilanterol (LABA); fluticasone furoate reduces airway inflammation via glucocorticoid receptor activation, umeclidinium produces bronchodilation through M3 muscarinic receptor inhibition, and vilanterol relaxes bronchial smooth muscle through beta2-adrenergic receptor stimulation and increased cyclic AMP.
Omalizumab is a recombinant humanized IgG1 monoclonal antibody that inhibits the binding of IgE to high-affinity IgE receptors (FceRI) on mast cells, basophils, and dendritic cells, resulting in FceRI down-regulation and reduction of IgE-mediated inflammatory responses; in CSU, omalizumab binds to IgE and lowers free IgE levels with down-regulation of IgE receptors, though the exact mechanism by which this results in CSU symptom improvement is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Trelegy Ellipta
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (11/12)
Xolair
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (11/12) · Qty limit (11/12)
UnitedHealthcare
Trelegy Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Xolair
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (6/8)
Humana
Trelegy Ellipta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Xolair
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Trelegy Ellipta.
Cost estimate not availableAccessia Health: Asthma - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Trelegy ElliptaView full Trelegy Ellipta profile
XolairView full Xolair profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.